The Trading Floor

[mick]

CLN: here is some news for transformation in their comapny.
Celsion Appoints New General Counsel
Monday May 3, 1:50 pm ET

COLUMBIA, Md.--(BUSINESS WIRE)--May 3, 2004--CELSION CORPORATION (AMEX:CLN - News) today announced that it has appointed Anita J. Finkelstein as Vice President and General Counsel. Ms. Finkelstein joins Celsion from her former position as a partner in the corporate practice at Venable LLP, where she served as Celsion's primary outside counsel. Ms. Finkelstein, who is also a certified public accountant, is a 1982 graduate of the Yale Law School.
Tony Deasey, Celsion's Chief Operating Officer, said, "We are delighted that Anita has joined the Celsion team. As we continue the evolution of Celsion from a medical device to a biopharmaceutical company, Anita will be invaluable in helping us to optimize our corporate structure and strengthen our already impressive intellectual property portfolio."

ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of treatment systems for cancer and other diseases using focused-heat energy, either administered alone, or in combination with other therapeutic devices, heat activated genes and heat activated drugs.

In January 2003, Celsion entered into a strategic alliance with Boston Scientific Corporation (NYSE:BSX - News) in which Boston Scientific will initially distribute the Prolieve Thermodilatation system worldwide. Boston Scientific currently owns approximately (7%) of Celsion's outstanding stock.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact:
Celsion Corporation, Columbia
Tony Deasey, 410-290-5390
[e-mail]
or
Equity Communications
Steve Chizzik, 973-912-0980
[e-mail]
or
Strategic Growth International, Inc.
Jennifer Zimmons, 212-838-1444
[e-mail]

Source: Celsion Corporation